Nanoparticles made by co-assembling the anti-inflammatory peptide KPV with an immunosuppressant targeted PepT1 transporters in inflamed gut tissue, effectively treating both acute and chronic colitis in mice.
Better than either aloneKPV peptide + FK506 co-assembled nanoparticles outperformed both KPV and FK506 monotherapy in reducing colitis inflammation and restoring gut barrier
What the researchers found
KPV-FK506 co-assembled nanoparticles targeted PepT1 on inflamed gut epithelium and outperformed either component alone in reducing inflammation, immune cell infiltration, and restoring tight junction proteins in both acute and chronic colitis models.
Why it matters
IBD affects millions worldwide with limited treatment options. A peptide-based nanodrug that targets inflamed tissue directly could deliver more effective treatment with fewer systemic side effects than current oral or IV immunosuppressants.
The numbers in context
The nanodrug targeted PepT1 transporters and treated both acute and chronic DSS-induced colitis models in mice.
How the study worked
Mouse study using DSS-induced acute (2.5% DSS) and chronic (4% DSS) colitis models. Compared nanoparticles (NPs), KPV peptide alone, FK506 alone, DSS control, and saline control. Assessed body weight, colon length, disease activity, inflammatory cytokines, oxidative stress markers, immune cell infiltration, and tight junction protein expression.
Who was studied
Mice with acute and chronic DSS-induced colitis
What this study cannot tell us
Mouse colitis model does not perfectly replicate human IBD. PepT1 expression patterns may differ in humans. Long-term safety, stability, and scalability of carrier-free nanoparticles are unknown. No comparison with current standard-of-care IBD treatments like biologics.
How to read the evidence
Preliminary evidence: well-designed mouse colitis study with comprehensive outcome measures, but no human data and the technology is in early development.
When this study was published
Published in 2024. Represents an innovative approach combining peptide therapeutics with nanotechnology for IBD treatment.
The bigger picture
Peptide-based nanomedicine is an emerging approach that combines the therapeutic properties of bioactive peptides with the targeting capabilities of nanotechnology. This study demonstrates that peptides can serve dual roles — both as the active drug and as part of the delivery vehicle — potentially simplifying drug design while improving targeted delivery to diseased tissue.
Questions still open
- Would PepT1-targeted peptide nanoparticles show similar efficacy in human IBD tissue?
- How do these nanoparticles compare to approved IBD biologics like anti-TNF antibodies?
- Can the carrier-free nanoparticle approach be scaled for pharmaceutical manufacturing?
Common questions
What is KPV peptide?
How do these nanoparticles target only inflamed gut tissue?
Read the original research
PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS.
Frontiers in pharmacology, 15, 1442876
Citation
Zhang, Daifang; Jiang, Longqi; Yu, Fengxu; Yan, Pijun; Liu, Yong; Wu, Ya; Yang, Xi. (2024). PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS.. Frontiers in pharmacology, 15, 1442876. https://doi.org/10.3389/fphar.2024.1442876